Cardiol Therapeutics, a late-stage life sciences company, announced it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead drug candidate CardiolRx™, which targets inflammation and fibrosis in conditions like pericarditis and myocarditis. CardiolRx™ has received Orphan Drug Designation from the FDA for pericarditis treatment, and the company is conducting pivotal Phase III trials. Cardiol is also developing CRD-38, a novel drug for inflammatory heart disease and heart failure. This presentation is an opportunity to update investors on clinical progress and future plans.
Palantir's stock rose about 28.8% from July to now, driven by a 93% year-over-year revenue increase to $1.94 billion in Q2 2026 and strong profitability. The company expanded its AI offerings through new partnerships with Nebius and PwC, alongside de...
Hybrid Power Solutions Inc. has established a larger manufacturing facility in Mississauga, Ontario, to increase production capacity for its fuel-free and hybrid portable power products. The new facility will feature dedicated production lines for th...
Nvidia's top insider, Director Mark Stevens, sold nearly $650 million worth of shares in two transactions, including the largest insider sale of the decade for Nvidia. This insider selling is part of a broader trend among big tech companies like Micr...
Graphene Manufacturing Group (GMG) announced that its G®CELLS graphene batteries have demonstrated exceptional durability, showing no performance loss after 489 cycles of fast charging and discharging within six minutes each. This performance signifi...
Oracle's connection to OpenAI, with about 47% of its remaining performance obligation linked to the AI firm, has shifted investor sentiment positively. Despite concerns over a $70 billion capital expenditure plan for fiscal 2027 and local resistance ...
